切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2021, Vol. 10 ›› Issue (06) : 570 -573. doi: 10.3877/cma.j.issn.2095-3232.2021.06.008

临床研究

保留肝右动脉的缩小右半肝切除术治疗肝硬化肝癌
陈骋1, 郑进方1,(), 陈劲松1, 刘俊1   
  1. 1. 570311 海口,海南省人民医院肝胆胰外科
  • 收稿日期:2021-07-22 出版日期:2021-09-23
  • 通信作者: 郑进方
  • 基金资助:
    海南省高等学校科学研究项目(Hnky2019-53)

Reduced right hepatectomy with reserved right hepatic artery for hepatocellular carcinoma complicated with liver cirrhosis

Cheng Chen1, Jinfang Zheng1,(), Jinsong Chen1, Jun Liu1   

  1. 1. Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital, Haikou 570311, China
  • Received:2021-07-22 Published:2021-09-23
  • Corresponding author: Jinfang Zheng
引用本文:

陈骋, 郑进方, 陈劲松, 刘俊. 保留肝右动脉的缩小右半肝切除术治疗肝硬化肝癌[J/OL]. 中华肝脏外科手术学电子杂志, 2021, 10(06): 570-573.

Cheng Chen, Jinfang Zheng, Jinsong Chen, Jun Liu. Reduced right hepatectomy with reserved right hepatic artery for hepatocellular carcinoma complicated with liver cirrhosis[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2021, 10(06): 570-573.

目的

探讨保留肝右动脉的缩小右半肝切除术治疗肝硬化肝细胞癌(肝癌)患者的安全性和疗效。

方法

回顾性分析2018年7月至2019年4月海南省人民医院行保留肝右动脉的缩小右半肝切除术的8例肝硬化肝癌患者临床资料。患者均签署知情同意书,符合医学伦理学规定。其中男7例,女1例;平均年龄(51±8)岁。术前采用三维重建软件测算全肝体积、残肝体积。分离、结扎门静脉右支,保留肝右动脉,沿左右肝缺血分界线右移1 cm切除右半肝,保留部分肝组织。观察患者围手术期情况。

结果

术前采用三维重建软件模拟右半肝切除,标准肝体积为(993±64)ml,标准右半肝切除的残肝体积为(348±32)ml,占标准肝体积的(35.0±2.3)%;切除平面右移1 cm后残肝体积为(428±34)ml,占标准肝体积的(42.7±1.4)%。所有患者均顺利完成保留肝右动脉的缩小右半肝切除术,术中未发生与操作有关的并发症,保留的肝组织颜色红润。手术时间(224±43)min,术中出血量(220±52)ml。术后肝功能指标呈一过性升高,随后出现下降,术后7 d基本恢复正常。术后腹腔引流液较少,均于术后6 d内拔除腹腔引流管。无发生小肝综合征及肝衰竭。

结论

保留肝右动脉的缩小右半肝切除术是一种安全有效术式,对于肝硬化肝癌的患者可能是一种新的术式选择,其有利于保留更多肝组织,预防术后肝衰竭。

Objective

To evaluate the safety and efficacy of reduced right hepatectomy with reserved right hepatic artery in the treatment of hepatocellular carcinoma (HCC) complicated with liver cirrhosis.

Methods

Clinical data of 8 HCC patients complicated with liver cirrhosis who underwent reduced right hepatectomy with reserved right hepatic artery in Hainan General Hospital from July 2018 to April 2019 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 7 patients were male and 1 female, aged (51±8) years on average. The volumes of total liver and residual liver before surgery were measured by 3D reconstruction software. The right branch of the portal vein was separated and ligated. The right hepatic artery was reserved. The right liver was resected 1 cm rightwards from the ischemic line of left and right lobe, and liver tissues were partially preserved. The perioperative conditions of patients were observed.

Results

Preoperatively, 3D reconstruction software was employed to simulate the right hepatectomy. The standard liver volume was (993±64) ml. The residual liver volume after standard right hepatectomy was (348±32) ml, accounting for (35.0±2.3)% of the standard liver volume. The residual liver volume was (428±34) ml after the resection plane was shifted 1 cm to the right side, accounting for (42.7±1.4)% of the standard liver volume. The right hepatectomy with reserved right hepatic artery were successfully completed in all the patients. No intraoperative complications occurred. The preserved liver tissues were found with normal redness. The operation time was (224±43) min and intraoperative blood loss was (220±52) ml. After operation, the parameters related to liver function were increased transiently, and decreased subsequently, and basically restored to normal at postoperative 7 d. After operation, the amount of abdominal drainage was slight, and all the abdominal drainage catheters were removed within postoperative 6 d. No small-for-size syndrome or liver failure occurred.

Conclusions

Reduced right hepatectomy with reserved right hepatic artery is a safe and efficacious surgery, which probably serves as a novel surgical option for HCC patients complicated with liver cirrhosis. It can preserve more liver tissues and prevent postoperative liver failure.

图1 一例肝硬化肝癌患者行保留肝右动脉的缩小右半肝切除术前CT三维重建
表1 肝硬化肝癌患者行保留肝右动脉的缩小右半肝切除围手术期情况(±s
[1]
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J].中国实用外科杂志, 2020, 40(2):121-138.
[2]
Zheng Y, Yang H, He L, et al. Reassessment of different criteria for diagnosing post-hepatectomy liver failure: a single-center study of1 683 hepatectomy[J]. Oncotarget, 2017, 8(51):89269-89277.
[3]
Sheng RF, Yang L, Jin KP, et al. Assessment of liver regeneration after associating liver partition and portal vein ligation for staged hepatectomy: a comparative study with portal vein ligation[J]. HPB, 2018, 20(4):305-312.
[4]
Pandanaboyana S, Bell R, Hidalgo E, et al. A systematic review and meta-analysis of portal vein ligation versus portal vein embolization for elective liver resection[J]. Surgery, 2015, 157(4):690-698.
[5]
Gong WF, Zhong JH, Lu Z, et al. Evaluation of liver regeneration and post-hepatectomy liver failure after hemihepatectomy in patients with hepatocellular carcinoma[J]. Biosci Rep, 2019, 39(8): BSR20190088.
[6]
Chin KM, Allen JC, Teo JY, et al. Predictors of post-hepatectomy liver failure in patients undergoing extensive liver resections for hepatocellular carcinoma[J]. Ann Hepatobiliary Pancreat Surg, 2018, 22(3):185-196.
[7]
Tustumi F, Ernani L, Coelho FF, et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis[J]. HPB, 2018, 20(12):1109-1118.
[8]
Watanabe N, Yamamoto Y, Sugiura T, et al. A predictive scoring system for insufficient liver hypertrophy after preoperative portal vein embolization[J]. Surgery, 2018, 163(5):1014-1019.
[9]
Vyas S, Markar S, Partelli S, et al. Portal vein embolization and ligation for extended hepatectomy[J]. Indian J Surg Oncol, 2014, 5(1):30-42.
[10]
张东欣,姜珊,董家鸿. 大范围肝切除术后肝功能衰竭的研究进展[J].中国现代普通外科进展, 2015(4):295-299.
[11]
Kang D, Schadde E. Hypertrophy and liver function in ALPPS: correlation with morbidity and mortality[J]. Visc Med, 2017, 33(6):426-433.
[12]
Chia DKA, Yeo Z, Loh SEK, et al. ALPPS for hepatocellular carcinoma is associated with decreased liver remnant growth[J]. J Gastrointest Surg, 2018, 22(6):973-980.
[13]
Lopez-Lopez V, Robles-Campos R, Brusadin R, et al. ALPPS for hepatocarcinoma under cirrhosis: a feasible alternative to portal vein embolization[J]. Ann Transl Med, 2019, 7(22):691.
[14]
曹彦龙,李巍. ALPPS治疗剩余肝体积不足的中晚期肝癌的现状[J].中华外科杂志, 2018, 56(4):307-311.
[15]
谭凯,杜锡林,陈安等.术前基于三维可视化技术精准设计肝离断面在ALPPS中的应用[J/OL].中华肝脏外科手术学电子杂志, 2020, 9(2):158-163.
[1] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[2] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[3] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[4] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[5] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[6] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[7] 王浩源, 汪海洋, 孙建明, 陈以宽, 祁小桐, 唐博. 腹腔镜与开放修补对肝硬化腹外疝患者肝功能及凝血的影响[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 654-659.
[8] 杭轶, 杨小勇, 李文美, 薛磊. 可控性低中心静脉压技术在肝切除术中应用的最适中心静脉压[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 813-817.
[9] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[10] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[11] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[12] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[13] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[14] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[15] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?